-

Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the UBS Global Healthcare Virtual Conference at 11:00 a.m. ET on May 26, 2021.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® Company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 14,000 people, including over 2,400 scientists and technicians, at more than 40 facilities across four continents, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Catalent, Inc.

NYSE:CTLT

Release Versions

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs

TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies...

Catalent’s SMARTag® ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc. presented new advancements in its SMARTag® antibody-drug conjugate (ADC) technology at the 16th World ADC San Diego conference....

Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company’s commitment to delivering unparalleled customer service and its focus on “championing the missions that matter.” The new approach reflects Catalent’s dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solution...
Back to Newsroom